China Biotech Services Holdings Limited (abbrev. China Biotech Services) filed its Monthly Return for the period ended 30 September 2026, confirming stable share capital and providing an update on outstanding convertible instruments.

Total authorised share capital remained unchanged at HKD 200.00 million, representing 2.00 billion ordinary shares with a nominal value of HKD 0.10 each. Issued share capital was likewise steady at 975.73 million shares; no treasury shares were held or cancelled during the month, and no new shares were issued. The issuer affirmed compliance with Hong Kong’s minimum public-float requirement of 25 per cent.

Convertible debt continues to represent the principal source of potential dilution: • US $6.00 million 2024 Convertible Bonds (maturing 27 December 2026) carry an adjusted conversion price of HKD 1.11, allowing for the issue of up to 42.43 million new shares. • US $35.00 million 2026 Convertible Bonds (maturing 20 February 2030) are convertible at HKD 0.66 per share, permitting up to 412.58 million new shares.

Combined, the two bond lines could add approximately 455.01 million shares, equivalent to about 46.6 per cent of the current issued share base, if fully converted. No share options, warrants, HDRs or other equity-linked instruments were outstanding or granted during the month.

Director Liu Xiaolin confirmed that all securities-related activities complied with Hong Kong Listing Rules and relevant regulations, and that all proceeds have been duly received. With no equity movements recorded in September, investors’ attention will likely stay on the potential dilution effect of the outstanding convertible bonds as they approach or enter conversion windows.